Objective: The objective of this study was to evaluate whether increased serum 25-hydroxyvitamin D 3 (25OHD 3 ) concentrations, in response to calcium/vitamin D (CaD) supplementation, are associated with improved lipids in postmenopausal women.
S ince the association between dyslipidemia and cardiovascular disease in women has been established, 1 there have been an increasing number of studies investigating calcium/vitamin D (CaD) and their effects on lipid concentrations. 2<4 Nearly a dozen randomized controlled trials (RCTs) have evaluated the association between supplemental calcium and the concentration of circulating cholesterol, generating inconsistent results. Although the results of one study in New Zealand 5 revealed a beneficial effect of calcium citrate on lipid profile, four studies showed no significant effects of calcium carbonate on cholesterol concentrations. 6<9 RCT reports evaluating the effects of vitamin D supplementation on plasma 25-hydroxyvitamin D 3 (25OHD 3 ) concentrations, coronary heart disease (CHD), and CHD risk factors (such as lipid parameters) are clearly lacking. The results of a few early studies analyzing the effects of vitamin D 3 compared with placebo found no significant changes in lipid concentrations in the intervention arm. 10, 11 One RCT of 464 postmenopausal women even reported that daily supplementation with 300 IU of vitamin D 3 was associated with a significant increase in low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), along with a significant decrease in highdensity lipoprotein cholesterol (HDL-C) and HDLYtoYLDL-C ratio, after 3 years of follow-up. 12 The results of another recent study also suggested that vitamin D may not improve lipid levels. 13 Data from this randomized, double-blind, placebo-controlled CaD cohort of the Women's Health Initiative (WHI) and from the subsample with measured 25OHD 3 concentrations were evaluated prerandomization and postrandomization to evaluate whether CaD oral supplementation and the subsequent achievement of higher plasma 25-hydroxyvitamin D (25OHD 3 ) concentrations affect lipid parameters. The objectives of this study were to evaluate the relationship between supplemental CaD, serum 25OHD 3 , and plasma cholesterol within the context of an RCT.
METHODS

Participant selection and randomization
The WHI CaD trial was a double-blind, randomized, placebocontrolled, parallel-group study designed to test the effects of CaD supplementation on hip fracture risk as the primary outcome, along with total fractures and colorectal cancer, in postmenopausal women. Participants enrolled in the WHI dietary modification trial, WHI hormone therapy (HT) trial, or both were invited to join the CaD trial at their first or second annual follow-up visit. Postmenopausal women aged 50 to 79 years who met the eligibility criteria joined the WHI HT and/or dietary modification trial between 1993 and 1998. They were invited to join the double-blind CaD trial a year later. Of those enrolling, 91% joined the CaD trial at the first annual visit, and 9% joined the following year. Women were recruited from the general community from multiple sites in the United States.
Details of the design, recruitment, randomization, data collection, intervention, and outcomes ascertainment procedures in the WHI CaD trial have been published previously. 14, 15 The eligibility criteria for enrollment in the CaD trial included many safety parameters (eg, no previous hypercalcemia or renal calculi) and no competing risk indicators (eg, no medical condition associated with survival of G3 y). Women were able to participate in the CaD trial even if they were taking their own supplemental calcium and/or vitamin D, provided their personal vitamin D supplementation did not exceed 600 IU/day (later changed to 1,000 IU/d). Study participants were randomized to calcium carbonate (with 1,000 mg of elemental calcium) combined with 400 IU of vitamin D 3 , taken in two divided doses daily. The remaining women were randomized to receive one oral placebo pill twice per day.
Biomarker subsample
Eligible participants included all white (n = 1,048; 509 active and 539 placebo), African-American (n = 458; 227 active and 231 placebo), and Hispanic (n = 247; 128 active and 119 placebo) women in the 6% subsample of the CaD trial who have available serum for 25OHD 3 testing at both year 1 (before CaD randomization) and year 3 (after CaD randomization) visits ( Fig. 1 ). The subsample was selected randomly from these totals to arrive at the final sample size of 600, which included 300 white participants, 200 African-American participants, and 100 Hispanic participants. Equal numbers for each group were selected from the intervention and placebo arms.
Biomarker analysis
Data on blood lipids were assessed before CaD randomization (prerandomization; both at baseline and at year 1) and after randomization (postrandomization; both at year 3 and at year 6; Fig. 2 ). 16 Blood samples were obtained from frozen stored samples (at j70-C) and assayed at Medical Research Laboratories Inc (Highland Heights, KY). Valid 25OHD 3 measurements were obtained from 576 participants at year 1 (before CaD randomization) and year 3 (after CaD randomization; Fig. 2 ). 25OHD 3 assay was performed on frozen stored serum samples using DiaSorin LIASON chemiluminescence (DiaSorin, Stillwater, MN). In this study, the intraclass correlation of 25OHD 3 for 60 blind duplicate pairs was 0.99.
Statistical methods
To determine whether CaD had a significant effect ( Fig. 3A ) on LDL-C and whether the effect of CaD was mediated through higher concentrations of 25OHD 3 (Fig. 3B ), we evaluated whether (1) CaD significantly increased 25OHD 3 (Fig. 3 , path a); (2) CaD had a significant effect on LDL-C ( Fig. 3 , path c); (3) the effect of CaD on LDL-C was attenuated after adjustment for 25OHD 3 (Fig. 3 , path c ¶); and (4) 25OHD 3 was significantly associated with LDL-C ( Fig. 3 , path b).
Step (2) establishes that there is an effect to be mediated. Lipid measures at baseline and years 1, 3, and 6 were fitted to a repeated-measures model with an unstructured covariance matrix to increase power and to confirm that CaD lowers LDL-C. 14 Using the complete 6% subsample, Hsia et al 14 did not find a significant CaD effect on HDL-C or TG. Although we also statistically tested these models on our data (a subsample of Hsia et al's data), we did not expect to find a significant effect prospectively, but we were interested to see whether these lipids were associated with 25OHD 3 . The distribution of TG was skewed; thus, TG was log-transformed for our analyses. Step (1) was addressed by fitting a second set of models, with 25OHD 3 as the response (log-transformed because of skewness). Ratios of mean 25OHD 3 (active divided by placebo) for the main effect of CaD and by subgroup are reported. Statistical significance of subgroups was based on tests of interactions. Steps (3) and (4) were addressed by adding 25OHD 3 , as a time-dependent variable, to the model in Step (2) . Because 25OHD 3 was not measured at baseline or year 6 and was 100% missing by design ( Fig. 2 ), missing 25OHD 3 values were imputed by carrying the postrandomization (prerandomization) measures forward (backward). As a secondary analysis, multiple imputation (n = 10) was performed by constructing a multivariate (25OHD 3 and LDL-C) longitudinal model (baseline, year 1, year 3, and year 6) with time-dependent fixed effects for CaD randomization, vitamin D supplementation, race/ethnicity, and random effects (random intercepts for CaD randomization period: pre or post). To mitigate potential confounding between 25OHD 3 and lipids, we included the following as covariates: age, race/ ethnicity, body mass index (BMI), smoking status, history of high blood cholesterol, diabetes mellitus, prior HT use, physical activity, total calcium intake, HT trial randomization arm, and dietary modification trial randomization arm. The covariates were included in all steps (steps 1-4) to allow for meaningful comparisons between models.
Multivariable-adjusted generalized additive mixed model estimates of the mean LDL-C, HDL-C, and TG levels as a smoothed function of 25OHD 3 were fitted using lipids and 25OHD 3 measurements at years 1 and 3 to ensure that 25OHD 3 and lipids were fitted on the appropriate scale for step (4) . Significance tests for 25OHD 3 Yvisit year and 25OHD 3 -CaD interactions were conducted to determine whether the relationships between 25OHD 3 and lipids remained unchanged regardless of visit year or treatment assignment. The smoothness of each spline fit was chosen objectively by generalized cross-validation.
The threshold for nominal significance was two-sided (P G 0.05) without adjustment for multiple testing. Statistical analyses were performed using SAS statistical software (version 9; SAS Institute, Cary, NC). Generalized additive models and corresponding figures were computed with R (version 2.11; R Development Core Team, 2010; http://www.R-project.org).
RESULTS
Baseline characteristics
Of the 600 women in the CaD trial subsample, 24 were excluded from the analyses: 1 participant did not have valid 25OHD 3 data and the remaining 23 had their visit 1 blood drawn after CaD randomization ( Fig. 1 ). Among the 576 women with valid data, 291 (50.5%) were receiving CaD and 285 (49.5%) were receiving placebo. The mean (SD) age at baseline was 61.8 (6.7) years. The women, on average, were 14.6 (9.7) years from menopause. The mean (SD) BMI and waist circumference were 30.5 (6.6) kg/m 2 and 90.7 (13.9) cm, respectively. The mean (SD) systolic blood pressure was 130.1 (16.5) mm Hg, and the mean (SD) LDL-C, HDL-C, and TG levels were 124.5 (33.1) mg/dL, 58.6 (15.0) mg/dL, and 149.2 (71.2) mg/dL, respectively. Demographics and comparisons between treatment and placebo groups are presented in Table 1 . No significant differences in baseline characteristics were seen between those on CaD and those on placebo.
Because 25OHD 3 is the exposure variable of interest, Table 2 presents the variables associated with 25OHD 3 . Analyzing baseline characteristics by LDL-C concentrations before randomization (broken into quartiles), we identified several findings across the range of 25OHD 3 concentrations. For example, 25OHD 3 concentration was inversely associated with being a current smoker (P G 0.001). African-American race was a risk factor for decreased 25OHD 3 , white race was a risk factor for increased 25OHD 3 , and Hispanic ethnicity had no influence. Concentrations of 25OHD 3 were negatively associated with BMI (P G 0.001) but positively associated with expenditure of energy from recreational physical activity (P G 0.001). Table 3 presents the baseline characteristics of women in the CaD trial subsample by quartiles of LDL-C (mg/dL) at year 1.
Effects of CaD on 25OHD 3 concentrations
Women on CaD had significantly increased mean (95% CI) postintervention 25OHD 3 Table 4 ). The mean (95% CI) postintervention 25OHD 3 concentration in women on CaD was 1.38 (1.29-1.47) times higher than that in women on placebo after covariate adjustment. Women taking CaD supplementation were more than twice as likely (risk ratio, 2.35; 95% CI, 1.71-3.22; P G 0.001) to have 25OHD 3 concentrations of 30 ng/mL or higher: 35.4% in the intervention arm versus 15.1% in the control arm. Similarly, women taking CaD supplementation were 1.58 times more likely (95% CI, 1.38-1.82; P G 0.001) to have 25OHD 3 concentrations of 20 ng/mL or higher: 75.6% in the intervention arm versus 47.7% in the control arm. The effect of CaD on 25OHD 3 concentration was not modified by covariates such as age, race/ethnicity, BMI, smoking, alcohol consumption, physical activity, HT use, or seasonal temporality ( Table 4 ).
Effects of CaD on lipids
Women randomized to CaD had a 4.46Ymg/dL decrease in LDL-C (95% CI, 0.41-8.51) compared with placebo (P = 0.03; Fig. 3A , path c; Table 5 ). There was a nonsignificant increase in HDL-C (P = 0.82) and a nonsignificant decrease in TG (P = 0.21). When 25OHD 3 concentration was included in the model, the effect of CaD on LDL-C was attenuated to a 3.24Ymg/dL decrease and was no longer significant (P = 0.13). Instead, 25OHD 3 concentration was a significant predictor of LDL-C (P = 0.04), where a 38% increase in 25OHD 3 was FIG. 3. A: Total effect of CaD on LDL-C (path c). B: CaD is hypothesized to lower LDL-C through 25OHD 3 . It is believed that randomization to CaD will increase circulating levels of 25OHD 3 (path a). Consequently, higher levels of 25OHD 3 , the mediating variable, will be associated with lower levels of LDL-C (path b). CaD will also exert a direct effect on LDL-C after adjustment for paths a and b (path c ¶). CaD, calcium/ vitamin D; LDL-C, low-density lipoprotein cholesterol; 25OHD 3 , 25hydroxyvitamin D 3 . associated with a 1.28Ymg/dL decrease in LDL-C (P = 0.04). The multiple imputation analysis yielded similar results where the effect of CaD was attenuated and no longer significant (P = 0.17), whereas 25OHD 3 was significantly associated with LDL-C (P = 0.01).
Association between 25OHD 3 and lipids
Modeling associations at both prerandomization and postrandomization visits and serum 25OHD 3 concentrations were significantly associated with all three cholesterol parameters ( Fig. 4 ). More specifically, higher 25OHD 3 concentrations were associated with higher HDL-C levels (P = 0.003). Lower TG was also associated with higher 25OHD 3 (P G 0.001), but it seemed that a certain threshold value of 25OHD 3 was needed (approximately 15 ng/mL) before this association became evident. Similarly, higher 25OHD 3 was associated with lower LDL-C levels (P = 0.02). The associations between 25OHD 3 and lipids were not modified by visit year (P interaction 9 0.10) or treatment assignment (P interaction 9 0.10).
DISCUSSION
In the current study, women on CaD had a significantly increased (by 38%) mean postintervention 25OHD 3 concentration compared with placebo (24.3 vs 18.2 ng/mL, respectively), and those randomized to CaD had a significant 4.46Ymg/dL decrease in LDL-C. The effect of CaD on 25OHD 3 was relatively constant across subgroups, and no statistically significant interactions were foundValthough older women, participants with low intake of vitamin D at baseline, and participants whose measurements of 25OHD 3 were obtained during winter had the largest absolute increase in 25OHD 3 concentrations (Table 4) . This makes sense, as these populations tend to have lower baseline 25OHD 3 concentrations and would be more likely to respond to supplementation. Nonsmokers and women who drink less alcohol also had larger absolute increases in 25OHD 3 .
FIG. 4.
Multivariable-adjusted generalized additive mixed model (GAMM) estimates of the mean LDL-C, HDL-C, and triglyceride (95% CI; shaded region) levels as a smoothed function of 25OHD 3 . Lipid and 25OHD 3 measurements at years 1 and 3 were included in GAMMs to incorporate both cross-sectional and longitudinal information. GAMMs included an indicator variable for pre/postYCaD randomization visit and were adjusted for age, race/ethnicity, body mass index, smoking status, history of high blood cholesterol, diabetes mellitus, prior HT use, physical activity, total calcium intake, HT randomization arm, DM randomization arm, CaD randomization arm, and CaD randomizationYvisit interaction. A random intercept was also included to account for within-participant correlation. The smoothness of each spline fit was chosen objectively by generalized cross-validation. CaD, calcium/vitamin D; HT, hormone therapy; LDL-C, low-density lipoprotein cholesterol; 25OHD 3 , 25-hydroxyvitamin D 3 ; HDL-C, high-density lipoprotein cholesterol.
Furthermore, as the serum concentration of 25OHD 3 increased, significant associations with all three lipid parameters were identified. Serum concentrations of 25OHD 3 mediated the effect of CaD on plasma LDL-C, as higher serum 25OHD 3 resulted in significantly lower LDL-C concentrations.
Our study is consistent with previous data, which suggest that vitamin D supplementation is beneficial for lipids, especially LDL-C, but has questionable, little, or no effect on total cholesterol, HDL-C, and TG. 16 Our study is also consistent with a previous WHI report that detected significant effects of CaD on LDL-C in the complete 6% subsample of approximately 2,400 women. 14 However, restriction to a subgroup (n = 1,219) 17 may have underpowered the study to detect differences. Considering the conflicting results for CaD in relationship to lipid parameters and their role as cardiovascular risk factors, little work has been performed to separate the two and to evaluate their individual contributions. It is important to acknowledge that in these studies, calcium and vitamin D could have opposite effects on lipid parameters, along with the presence of other potential confounding factors such as the dosage of supplementation, compliance, type of calcium, and the duration of treatment or follow-up. Although we do not know definitively how much of a factor oral calcium was in the lipid findings, the results of previous studies question whether calcium carbonate, used in this trial, has a significant effect on plasma lipids 6<9 compared with calcium citrate. 5 Therefore, assessing the effect of combined supplementation on lipid concentrations without measuring serum 25OHD 3 or calcium concentrations may not be able to discern a true association between vitamin D supplementation and changes in lipid parameters. Hence, our study measured serum 25OHD 3 concentrations and explored the association between 25OHD 3 (as a mediator) and vitamin D supplementation, as well as circulating lipid concentrations.
We were able to control for potential confounding variables and included a direct measurement of serum 25OHD 3 both prerandomization and postrandomization, allowing for a better assessment of vitamin D's contribution to the lipid findings, examining concentrations, and assessing multiple confounders. Therefore, our findings indicate that CaD may have favorable effects on lipids by increasing levels of serum 25OHD 3 . In addition to the beneficial and significant lowering of LDL-C associated with higher posttreatment 25OHD 3 , we observed that all three lipid parameters were favorably associated with higher 25OHD 3 concentrations. Higher concentrations of 25OHD 3 were associated with higher concentrations of HDL-C and lower concentrations of LDL-C and TG (after reaching the threshold of approximately 15 ng/mL). However, CaD was not found to increase HDL-C or to lower TG, consistent with previous WHI studies, 14 possibly because the associations between 25OHD 3 and these two lipids are more modest than the associations between 25OHD 3 and LDL-C, as indicated in Figure 4 .
Why some studies suggest that vitamin D supplementation and/or higher serum concentrations of 25OHD are associated with improved lipid parameters 2, 18, 19 whereas some do not 12, 20 needs further exploration. The results of a recent study suggest an observational association between higher concentrations of 25OHD 3 and more favorable lipid parameters, yet women who increased their 25OHD 3 levels had an overall worsened cholesterol profile. 13 This could suggest that the observational association is attributable to confounding variables with no prospective benefit to supplementation. The observational results could also be related to a lack of methodological control and range of doses compared with RCTs. Our results suggest a prospective improvement of LDL-C in response to CaD supplementation, which was mediated by increased serum concentrations of 25OHD 3 . How do we reconcile this result with other studies showing worsened lipid parameters after vitamin D supplementation? 12 One possibility is that women with the greatest increase in 25OHD 3 may have been those most compliant with CaD study pills and HT among those in the HT arm of the WHI. Because HT significantly lowers LDL-C and raises HDL-C, this could be an important factor.
The women most compliant with study pills may also have been those most compliant with lifestyle modification (such as increasing physical activity and weight loss) during follow-up, which could have contributed to the greater increase in 25OHD 3 . Because many of the women were on HT, another possibility is the hypothesized synergistic relationship between vitamin D and estrogen therapy/HT, 21 which may have allowed our population, compared with other prospective studies, 12, 20 to achieve a lipid profile benefit from vitamin D. Clearly, this From a multivariable-adjusted repeated-measures regression model of 25OHD 3 , measured at year 1 (just before CaD randomization) and year 3 (2 y postrandomization), regressed on CaD randomization group and covariates. 25OHD 3 was fitted on the log-transformed scale, and ratios (95% CIs) were backtransformed and presented on the original scale. potential synergy between vitamin D and estrogen therapy/HT needs to be further investigated. The potential synergistic role of CaD also needs to be considered. 22 The Institute of Medicine (IOM) reviewed more than 1,000 studies on vitamin D and a range of health outcomes including, but not limited to, cancer, cardiovascular disease, hypertension, diabetes, immune system, and reproductive outcomes. The IOM determined that, with regard to the nonskeletal health outcomes reviewed (including studies on cardiovascular health), results often were mixed and inconclusive. 23, 24 It is also important to interpret with caution the observational literature on 25OHD and CaD, as confounding variables can easily influence the results and can be difficult to control for. These studies often have risk factors that are closely connected to the study population, which can lead to lower vitamin D levels, CHD, hypercholesterolemia, or other CHD risk factors. In accord with these cautions, the results of a recent study showed that the association between baseline 25OHD concentrations and more favorable lipid parameters was not subsequently seen with increasing vitamin D levels from less than 20 ng/mL to more than 30 ng/mL. 13 Our study, therefore, is unique in that associations between 25OHD 3 and LDL-C were consistent with the prospective results of a significant improvement in LDL-C secondary to a posttreatment increase in 25OHD 3 concentrations. The results of previous studies have suggested that between 18% and 53% of individuals who took oral vitamin D supplementation (between 2,000 and 8,000 IU/d) did not increase their serum 25OHD 3 concentration into the reference range. 25, 26 For all subgroups of total vitamin D intake at baseline (even for those consuming G100 IU/d), the mean 25OHD 3 for women randomized to CaD exceeded 20 ng/mL (a concentration deemed adequate in the IOM report; Table 4 ). 23, 24 Although previous studies have suggested that vitamin D supplementation is beneficial for improving lipid parameters, 2 the current study helps in confirming these findings. This population of women who ingested 400 IU of vitamin D and 1,000 mg of calcium carbonate daily had a 6Yng/mL significantly higher 25OHD 3 concentration than those on placebo.
Among the eligible women, we selected 600 participants for 25OHD 3 measurements at years 1 and 3; hence, the study was somewhat limited by the sample size. Although complete data were available to assess the RCT effects of CaD on LDL-C and 25OHD 3 , imputation was used in the mediation analysis to extrapolate data from years 1 and 3 to baseline and year 6, respectively. Women were also allowed to take their own vitamin D supplementation, which obviously varied. Although these may be viewed as limitations, we followed 25OHD 3 concentrations and confirmed through statistical testing the validity of these approaches and methods. There was also a potential for confounding, especially in the observational portion of the study, by variables such as BMI, outdoor physical activity, diet, poor health, and other lifestyle choices such as smoking. In addition to the prospective, double-blind, randomized, placebocontrolled design, adjustment for covariates such as age, BMI, and season was a strength of this study. The inclusion of 25OHD 3 measurementsVto help explain the prospective association between exposure (CaD supplementation) and outcome parameters (change in lipids)Vwas another major advantage. Given the limitations, it would clearly be advantageous to confirm these findings with additional high-quality prospective studies and randomized clinical trials.
CONCLUSIONS
Oral CaD (1,000 mg of elemental calcium combined with 400 IU of vitamin D 3 daily) results in a significantly increased concentration of 25OHD 3 and decreased LDL-C levels. We also demonstrated that higher serum concentrations of 25OHD 3 are significantly associated with improvement in all three lipid parameters tested (HDL-C, LDL-C, and TG). These results support the hypothesis that higher concentrations of 25OHD 3 , in response to CaD supplementation, are associated with improved LDL-C. Although further studies are needed to determine whether these findings translate into clinically meaningful results, this should be viewed as a reminder that women at higher risk for 25OHD 3 deficiency should consider supplementation with CaD. Adjusted for age, race/ethnicity, body mass index, smoking status, history of high blood cholesterol, diabetes mellitus, prior HT use, physical activity, total calcium intake, HT randomization arm, and DM randomization arm. 
